### INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/019800

A. CLASSIFICATION OF SUBJECT MATTER Int.Cl<sup>7</sup> A61K45/00, 48/00, 31/7088, 41/00, A61P35/00, 35/02, 35/04

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
Int.Cl<sup>7</sup> A61K45/00, 48/00, 31/7088, 41/00, A61P35/00, 35/02, 35/04

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAPLUS (STN), MEDLINE (STN), BIOSIS (STN), EMBASE (STN)

### C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	JP 2001-502553 A (PHONE-POULENC RORER S.A.), 27 February, 2001 (27.02.01), Particularly, Claims; page 5, lines 3 to 12; examples & EP 941252 A1 & WO 1998/18825 A1	1,6 2-5
XA	JP 2001-511815 A (Canji, Inc.), 14 August, 2001 (14.08.01), Particularly, Claims; page 11, line 3 to page 12, line 7; examples & EP 969720 A1 & WO 1998/35554 A1 & US 2003/0060434 A1	1,6 2-5

×	Further documents are listed in the continuation of Box C.		See patent family annex.	
* "A"	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	
"E"	filing date		document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	
cited to establish the publication date of another citation or other special reason (as specified)		"Y"	considered to involve an inventive step when the document is	
"O" "P"	document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed	«&»	combined with one or more other such documents, such combination being obvious to a person skilled in the art  document member of the same patent family	
Date of the actual completion of the international search 29 March, 2005 (29.03.05)		Date	of mailing of the international search report  12 April, 2005 (12.04.05)	
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer		
Facsimile No.		Telephone No.		

Form PCT/ISA/210 (second sheet) (January 2004)

# INTERNATIONAL SEARCH REPORT

International application No. PCT/JP2004/019800

ategory*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
X A	JP 2002-531396 A (Pfizer Products Inc.), 24 September, 2002 (24.09.02), Particularly, Claims; page 28, line 11 to page 29, line 23; examples & EP 1137418 A1 & WO 2000/032175 A1 & US 2002/0048271 A1	1,6 2-5	
<b>X A</b>	JP 10-512559 A (RHONE-POULENC RORER S.A.), 02 December, 1998 (02.12.98), Particularly, Claims; page 12, line 17 to page 14, line 5; examples & EP 800399 Al & WO 1996/22101 A1 & US 2001/0021395 A1	1,6 2-5	
XA	JP 10-503361 A (Board of Regents, the University of texas System), 31 March, 1998 (31.03.98), Particularly, Claims; page 7, line 19 to page 9, line 3; examples & JP 10-503476 A & EP 725791 A1 & EP 575518 A1 & EP 760675 A1 & EP 1157702 A1 & WO 1995/015680 A1 & US 6017524 A & US 5747469 A & US 6069134 A & US 6143290 A	1,6 2-5	
A	WO 2002/052007 A1 (LOCOMOGENE, INC.), 04 July, 2002 (04.07.02), (Family: none)	1-6	
A	WO 2003/008573 A2 (MILNER, Anne, Josephine), 30 January, 2003 (30.01.03), & JP 2004-535813 A & EP 1432799 A2 & US 2004/235171 A1	1-6	

# BEST AVAILABLE COPY

# INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP2004/019800

	101/012004/019600	
Box No. II	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)	
l. X Claim becau Claims and thus is not r Rule 39	mal search report has not been established in respect of certain claims under Article 17(2)(a) for the following reason in Nos.: 7-22  use they relate to subject matter not required to be searched by this Authority, namely:  7 to 22 pertain to methods for treatment of the human body by there is relate to a subject matter which this International Searching Author required, under the provisions of Article 17(2)(a)(i) of the PCT of the Regulations under the PCT, to search.  In Nos.:  Use they relate to parts of the international application that do not comply with the prescribed requirements to such an at that no meaningful international search can be carried out, specifically:	apy ity and
	ns Nos.: use they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).	
Box No. III	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)	
1. As all r claims. 2. As all s any add 3. As only	required additional search fees were timely paid by the applicant, this international search report covers all searchable.  searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of ditional fee.  y some of the required additional search fees were timely paid by the applicant, this international search report cover tose claims for which fees were paid, specifically claims Nos.:	
4. No requestricted restricted Remark on Prof	uired additional search fees were timely paid by the applicant. Consequently, this international search report is ed to the invention first mentioned in the claims; it is covered by claims Nos.:  test  The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.	

<Subject of search>

Claims 1 and 2 relate to medicinal compositions containing compounds defined by desired properties "a substance promoting the activity of the cancer suppressor gene p53 or the protein p53" and "a substance inhibiting the expression and/or function of synoviolin". Although claims 1 and 2 involve any compounds having these properties, it is recognized that only small parts of the claimed compounds are supported by the description in the meaning within PCT Article 6 and disclosed therein in the meaning within PCT Article 5.

Although the common technical knowledge at the point of the application is taken into consideration, the scopes of the compounds having the properties "a substance promoting the activity of the cancer suppressor gene p53 or the protein p53" and "a substance inhibiting the expression and/or function of synoviolin" cannot be specified. Thus, claims 1 and 2 do not comply with the requirement of clearness under PCT Article 6 too.

Such being the case, the search was made exclusively on the relationship between the effect of promoting the activity of the cancer suppressor gene p53 or the protein p53 and cancer treatment and medicinal compositions efficacious in treating cancer which contains siRNA or shRNA for genes encoding synoviolin as presented in detail in the description and specified in claims 3 to 5.